Recce Pharmaceuticals Ltd
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James Hamilton-Bray Graham
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Aurora Place Sydney NSW Australia 2000
- IPO Date
- Aug 12, 2022
- Website
- recce.com.au
- Similar Companies
- Business
- Recce Pharmaceuticals Ltd (ASX:RCE; OTCQX:RECEF), a clinical-stage biotechnology company headquartered in Sydney, Australia, and founded in 2007, discovers, develops and commercializes a proprietary new class of synthetic polymer anti-infectives designed to address antibiotic-resistant superbugs and emerging viral pathogens through a universal mechanism of action that targets bacterial and viral cell walls without promoting resistance. The company's lead product candidate, RECCE 327 (R327), is a broad-spectrum synthetic anti-infective available in intravenous, topical gel and nebulized formulations for treating serious bacterial infections including sepsis, urinary tract infections (UTIs), urosepsis, diabetic foot infections (DFI), acute bacterial skin and skin structure infections (ABSSSI), burn wounds and infections caused by ESKAPE pathogens such as Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae and Enterobacter species; RECCE 435 (R435) is an oral formulation for bacterial infections; and RECCE 529 (R529) targets viral infections including respiratory pathogens. Operations span Australia, the United Kingdom, the United States and Southeast Asia, with a focus on priority pathogens recognized by the World Health Organization and Qualified Infectious Disease Product (QIDP) designation from the US FDA for R327, granting Fast Track status and 10 years of market exclusivity post-approval. In 2025, Recce announced a A$30 million debt facility to fund Phase III trials, completed a A$5.0 million placement and entitlement offer raising up to A$15.8 million to support registrational Phase III trials for DFI in Indonesia and ABSSSI in Australia following positive Phase II topical gel results exceeding 93% efficacy, secured Indonesian regulatory approval for Phase III DFI topical trials, partnered with the US Army and US Department of Defense receiving US$2 million for R327 gel in burn wound infections, expanded Phase II DFI trials and advanced nebulized R327 for lung infections; earlier initiatives included a 2024 strategic partnership with Indonesian biotech Etana for clinical acceleration, Phase II ABSSSI trial dosing completion and multiple patent grants in China, Israel and Canada. The company, formerly Recce Limited until its 2017 name change, maintains a single-segment focus on anti-infective research and development with strategic collaborations such as Murdoch Children's Research Institute for gonorrhoeae, abscessus and E. coli trials.
Recce Pharmaceuticals advances dual Phase 3 programs and MENA licensing strategy in strong June quarter
Halliburton tops Q2 earnings estimates as CEO warns of softer oilfield services market
Recce Pharmaceuticals extends share purchase plan deadline to July 24
Recce patent extends Vietnam protection to 2041 - ICYMI
Amazon seen well-positioned going into Q2 report on AWS momentum, Prime Day spending
Dow dips but Nasdaq higher after soft CPI and good bank earnings offset IBM shocker
Crypto's landmark Clarity Act stalls in Senate as passage odds sink to 39%
Small Cap Watch: biotech, gold and critical minerals explorers deliver key milestones
Recce Pharmaceuticals bolsters cash position with A$3.67 million tax refund ahead of Phase 3 milestones
Panmure Liberum says wine takeover exposes deep value at Naked and Virgin
Recce raises A$4M as it advances anti-infective trials and commercial licensing plans; another $4M to come in SPP
Nasdaq set to take another hit from rotation out of tech before quarter-end
Data layer emerges as the defining battleground of the AI revolution
Recce secures path to MENA commercialisation - ICYMI
Canada enters technical recession as GDP contracts for second straight quarter
Recce Pharmaceuticals advances US Army burn wound program and Indonesia Phase 3 trial in March quarter
Recce clears Indonesian Phase 3 site inspection as diabetic foot infection trial advances
Apple after Cook: what the hardware era means for investors
CRISM Therapeutics shares jump on positive prostate cancer drug delivery data
SEEEN shares climb as AIM company acquires profitable video platform MEDIAL for £1.2m